Suppressive antibiotic treatment of CF patients with chronic P. aeruginosa airway infection is the standard of care in Europe and North America. With the recent inhaled aztreonam approval, there are now three antipseudomonal antibiotic classes that are readily available and commonly utilized to manage chronic P. aeruginosa airway infections: polymyxins (colistimethate), aminoglycosides (gentamicin, tobramycin) and beta lactams (aztreonam). These agents have all been studied and developed as monotherapies, but there is growing interest in the use of these agents in various combinations in individual patients to improve outcomes and extend the period of efficacy of suppressive treatment.
Review how treatment patterns among patients among US CF patients have changed with the introduction of a third class of inhaled antipseudomonal antibiotic
Discuss the ramifications of multiple inhaled antibiotic use with respect to design and execution future inhaled antibiotic studies of either newer members of existing antibiotic classes or new antibiotic classes
Examine how the results of large clinical studies conducted to date have informed our understanding (or lack thereof) of the mechanism(s) of inhaled antibiotic efficacy